<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478776</url>
  </required_header>
  <id_info>
    <org_study_id>15176</org_study_id>
    <nct_id>NCT01478776</nct_id>
  </id_info>
  <brief_title>The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics</brief_title>
  <official_title>The Impact of Omega-3 Supplementation on Acylation Stimulating Protein(ASP), Retinol-binding Protein 4 (RBP4) and Lipocalin-2 (LCN2) Gene Expression of ASP Receptor (C5L2) in WBC of Patient With Diabetes Type 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the comparison between the effects of supplementation with omega-3
      or placebo for 10 weeks in type 2 diabetics
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adipose tissue is recognized as an important endocrine organ in human. Not only it has
      function of storing unlimited energy but also its secretory roles is subject to intense
      research in recent years. Acylation stimulating protein(ASP), Retinol-binding protein 4
      (RBP4) and lipocalin-2 (LCN2) are circulating adipokines elevated in diabetes. C5L2 is a
      G-protein-coupled receptor. activation of C5L2 by ASP, has been shown. Fatty acids may
      influence the expression of adipokines. Epidemiological studies showed that omega-3 reduce
      the development of insulin resistance and diabetes. Because fatty acids are the main
      component of adipose tissue, it is essential interest to clarify the biological effects of
      omega-3 on the expression of relevant adipokines.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum total cholesterol</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>serum High-density lipoprotein (HDL) cholesterol</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>serum Low-density lipoprotein (LDL) cholesterol</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>serum triglycerides (TG) level</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>postprandial triglycerides</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>complete blood count(CBC)</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fasting plasma glucose(FPG)</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycated hemoglobin (Hb A1c)</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>acylation stimulating protein (ASP)</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>lipocalin-2 (LCN2)</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinol-binding protein 4 (RBP4)</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>non-esterified fatty acids (NEFA)</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>insulin</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>postprandial ASP</measure>
    <time_frame>chage from baseline at 10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>gene expression of C5L2</measure>
    <time_frame>change from baseline at 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>diabetes, omega-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient with type 2 diabetes who receive 4gr/day omega-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, diabetes</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient with type 2 diabetes who receive 4 cap of placebo/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omega-3</intervention_name>
    <description>4 cap 1 gr omega-3 per day for 10 weeks</description>
    <arm_group_label>diabetes, omega-3</arm_group_label>
    <other_name>n-3 fatty acids,n-3 PUFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>patient with type 2 diabetes who receive 4 cap placebo/day for 10 weeks</description>
    <arm_group_label>placebo, diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  literate

          -  Willingness to participation

          -  Diabetic patients 30-65 years old

          -  Body mass index in the range 18.5-40

          -  Avoidance of dietary supplements

          -  vitamins and herbal products at least 2 weeks before and throughout the intervention

        Exclusion Criteria:

          -  people who have used omega-3 supplements in last 3 months

          -  Having chronic renal disease

          -  hepatic disease

          -  gastrointestinal disease

          -  hematological disorders

          -  hypothyroidism or hyperthyroidism

          -  Treatment with Orlistat or sibutramine for weight loss

          -  Pregnancy and lactation

          -  Treatment with insulin or Thiazolidinediones
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tehran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP</keyword>
  <keyword>LCN2</keyword>
  <keyword>RBP4</keyword>
  <keyword>C5L2</keyword>
  <pending_results>
    <submitted>December 10, 2013</submitted>
    <returned>January 29, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

